Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals

Drug Profile

Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals

Alternative Names: FR-210575; Stroke research programme - Astellas Pharma/Quark Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma; Quark Biotech
  • Developer Astellas Pharma; SBI Biotech
  • Class Cinnamates; Small molecules; Triazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in USA
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 11 Aug 2003 Quark and Fujisawa have extended their research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top